FY2026 EPS Estimates for CMPS Decreased by Cantor Fitzgerald

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Investment analysts at Cantor Fitzgerald decreased their FY2026 earnings estimates for COMPASS Pathways in a research note issued to investors on Wednesday, November 5th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($1.91) per share for the year, down from their previous forecast of ($0.87). The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share.

A number of other equities analysts have also issued reports on CMPS. Canaccord Genuity Group restated a “buy” rating and set a $15.00 target price on shares of COMPASS Pathways in a research report on Friday, August 1st. Morgan Stanley increased their price objective on COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Wednesday. BTIG Research raised their target price on shares of COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Monday, October 13th. HC Wainwright decreased their price target on COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, August 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.88.

COMPASS Pathways Stock Performance

CMPS traded down $0.16 during trading on Friday, hitting $5.43. 489,203 shares of the stock were exchanged, compared to its average volume of 1,826,181. The company has a quick ratio of 8.82, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. COMPASS Pathways has a 1-year low of $2.25 and a 1-year high of $7.09. The stock has a fifty day moving average price of $5.77 and a two-hundred day moving average price of $4.66. The firm has a market capitalization of $520.95 million, a P/E ratio of -2.00 and a beta of 2.22.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02.

Institutional Trading of COMPASS Pathways

Several large investors have recently bought and sold shares of CMPS. CWM LLC raised its stake in shares of COMPASS Pathways by 19.2% during the third quarter. CWM LLC now owns 15,650 shares of the company’s stock valued at $90,000 after purchasing an additional 2,525 shares during the period. Conservest Capital Advisors Inc. increased its stake in COMPASS Pathways by 32.5% during the 2nd quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock worth $57,000 after buying an additional 5,000 shares during the period. GAMMA Investing LLC lifted its holdings in COMPASS Pathways by 93.6% in the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock worth $30,000 after buying an additional 5,003 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in COMPASS Pathways by 46.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after buying an additional 5,817 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of COMPASS Pathways by 67.0% during the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 23,842 shares of the company’s stock valued at $67,000 after acquiring an additional 9,569 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.